Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

A Denver man said he's learning to navigate so-called "brain fog" after undergoing chemotherapy six years ago.

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

NEW YORK – Seattle-based BrainChild Bio announced Friday that it is advancing its leading drug candidate, a CAR T-cell therapy targeting the immune checkpoint B7-H3 to a registrational trial, to ...

Doctors discuss the prevalence, risks and treatments of metastatic melanoma, as Teddi Mellencamp reveals the latest updates ...

Researchers at Baylor College of Medicine, Texas Children's Hospital, the Hospital for Sick Children in Toronto and ...

Illuccix has gained significant market share due to changes in clinical practice and successful distribution. The company requires minimal capital and is expected to generate very high returns as it ...

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.

The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...